Intra-Cellular Financial Statements From 2010 to 2022

ITCI
 Stock
  

USD 47.46  1.25  2.57%   

Intra-Cellular Ther financial statements provide useful quarterly and yearly information to potential Intra-Cellular Ther investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Intra-Cellular Ther financial statements helps investors assess Intra-Cellular Ther's valuation, profitability, and current liquidity needs.
Intra-Cellular Ther does not presently have any fundamental trends for analysis.
.
  
Check Intra-Cellular Ther financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intra-Cellular main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Intra-Cellular financial statements analysis is a perfect complement when working with Intra-Cellular Ther Valuation or Volatility modules. It can also supplement Intra-Cellular Ther's financial leverage analysis and stock options assessment as well as various Intra-Cellular Ther Technical models . Please see the analysis of Intra-Cellular Ther Correlation against competitors.

Intra-Cellular Price to Earnings To Growth Analysis

Intra-Cellular Ther's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
PEG Ratio 
 = 
PE Ratio 
EPS Growth 
More About Price to Earnings To Growth | All Equity Analysis

Current Intra-Cellular Ther Price to Earnings To Growth

    
  (0.08) X  
Most of Intra-Cellular Ther's fundamental indicators, such as Price to Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra-Cellular Ther is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Compare to competition

Based on the latest financial disclosure, the price to earnings to growth indicator of Intra-Cellular Ther is roughly -0.08 times. This is 111.27% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The price to earnings to growth for all United States stocks is 101.64% higher than that of the company.

Intra-Cellular Ther Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Intra-Cellular Ther's current stock value. Our valuation model uses many indicators to compare Intra-Cellular Ther value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intra-Cellular Ther competition to find correlations between indicators driving Intra-Cellular Ther's intrinsic value. More Info.
Intra-Cellular Ther is currently regarded as number one stock in working capital category among related companies. It is currently regarded as number one stock in total asset category among related companies fabricating about  1.35  of Total Asset per Working Capital. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Intra-Cellular Ther by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Intra-Cellular Ther's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intra-Cellular Ther's earnings, one of the primary drivers of an investment's value.

About Intra-Cellular Ther Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Intra-Cellular Ther income statement, its balance sheet, and the statement of cash flows. Intra-Cellular Ther investors use historical funamental indicators, such as Intra-Cellular Ther's revenue or net income, to determine how well the company is positioned to perform in the future. Although Intra-Cellular Ther investors may use each financial statement separately, they are all related. The changes in Intra-Cellular Ther's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Intra-Cellular Ther's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Intra-Cellular Ther Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Intra-Cellular Ther. Please read more on our technical analysis and fundamental analysis pages.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intra-Cellular Ther in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intra-Cellular Ther's short interest history, or implied volatility extrapolated from Intra-Cellular Ther options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Intra-Cellular Ther Correlation against competitors. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.